Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma

Cancer Science

Volumn 104, Issue 6, 2013, Pages 765-772

  Inoue, Keiji ^a   Fukuhara, Hideo ^a   Kurabayashi, Atsushi ^a   Furihata, Mutsuo ^a   Tsuda, Masayuki ^a   Nagakawa, Keisuke ^b   Fujita, Hirofumi ^b   Utsumi, Kozo ^b   Shuin, Taro ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; DEFEROXAMINE; FERROCHELATASE; PROTOPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAPILLARY ENDOTHELIUM; CELL DEATH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; THERAPY EFFECT; TRANSITIONAL CELL CARCINOMA; UMBILICAL VEIN ENDOTHELIAL CELL;

AMINOLEVULINIC ACID; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL LINE; DEFEROXAMINE; ENZYME INHIBITORS; FERROCHELATASE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTOPORPHYRINS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878166976     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12147     Document Type: Article

References (23)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 2012; 42: 139-47.
3. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 2000; 27: 1-13, vii.
4. Krammer B, Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci 2008; 7: 283-9.
5. Friesen SA, Hjortland GO, Madsen SJ et al. 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review). Int J Oncol 2002; 21: 577-82.
6. Fukuhara H, Inoue K, Kuno T et al. Preliminary experience of photodynamic diagnosis of positive margin during radical prostatectomy by oral 5-aminolevulnic acid. Int J Urol 2011; 18: 585-91.
7. Inoue K, Fukuhara H, Shimamoto T et al. Comparison between intravesical and oral administration of 5-aminolevulinic acid in the clinical benefit of photodynamic diagnosis for non-muscle invasive bladder cancer. Cancer 2012; 118: 1062-74.
8. Zhao B, He YY. Recent advances in the prevention and treatment of skin cancer using photodynamic therapy. Expert Rev Anticancer Ther 2010; 10: 1797-809.
9. Fujita H, Utsumi T, Muranaka S et al. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 2005; 69: 1773-84.
10. Okimura Y, Fujita H, Ogino T et al. Regulation of 5-aminolevulinic acid-dependent protoporphyrin IX accumulations in human histiocytic lymphoma U937 cells. Physiol Chem Phys Med NMR 2007; 39: 69-82.
11. Amo T, Kawanishi N, Uchida M et al. Mechanism of cell death by 5-aminolevulinic acid-based photodynamic action and its enhancement by Mn2+, deferoxamine, and NOC-18 in human histiocytic lymphoma cell line U937. Cell Biochem Funct 2009; 27: 503-15.
12. Ogino T, Kobuchi H, Munetomo K et al. Serum-dependent export of protoporphyrin IX by ATP-binding cassette transporter G2 in T24 cells. Mol Cell Biochem 2011; 358: 297-307.
13. Inoue K, Takashi K, Kamada M et al. Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX-accumulation in human urothelial carcinomas. Pathobiology 2009; 76: 303-14.
14. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 1976; 36: 2326-9.
15. Laustriat G. Molecular mechanism of photosensitization. Biochemie 1986; 68: 771-8.
16. Steinbach P, Weingandt H, Baumgartner R, Kriegmair M, Hofstadter F, Knuchel R. Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid. Photochem Photobiol 1995; 62: 887-95.
17. Inoue K, Slaton JW, Karashima T et al. The Prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000; 6: 4866-73.
18. Dinney CP, Fishbeck R, Singh RK et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995; 154: 1532-8.
19. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003; 9: 886-99.
20. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-14.
21. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: past, present and future. Urol Res 2001; 29: 396-405.
22. Pinthus JH, Bogaards A, Weersink R, Wilson BC, Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 2006; 175: 1201-7.
23. Folkman J. Fighting cancer by attacking its blood supply. Sci Am 1996; 275: 150-4.